UNASSIGNED: Retrospective study of patients with ENB treated between 1984-2022. A total of 20 patients were identified, 13 men and 7 women, aged between 20 and 76 years.
UNASSIGNED: Eleven patients were stage C of the modified Kadish staging system at initial presentation, 7 stage B, 1 stage A and 1 stage D. Seventeen patients underwent surgery alone or combined with adjuvant treatment (radiotherapy or chemoradiotherapy). The majority of the patients (71.4%) treated with surgery alone were stage B, whereas most of the patients (63.6%) that underwent surgery combined with adjuvant treatment were stage C. Five of the 7 patients treated with surgery alone had a locoregional recurrence. Two of the 10 patients treated with surgery followed by adjuvant treatment had relapsed, locoregionally and at a distance, respectively. One patient was treated with chemotherapy and 2 patients were treated with chemoradiotherapy and neoadjuvant chemotherapy followed by chemoradiotherapy, respectively. The recurrence and persistence rates were 35% and 15%, respectively. The median time from the end of the first treatment to recurrence was 20.9 months. Two- and 5-year overall survival rates were 83.9% and 77.9%; while progression-free survival rates were 76.7% and 61.0%, respectively.
UNASSIGNED: Sixty percent of patients were treated with a multimodal approach, which appeared to be a favorable strategy for the majority of patients.
■1984-2022年间接受ENB治疗的患者的回顾性研究。总共确定了20名患者,13男7女,年龄在20至76岁之间。
■11例患者在初次就诊时处于改良Kadish分期系统的C期,7阶段B,1期A和1期D。17例患者接受了单独手术或联合辅助治疗(放疗或放化疗)。仅接受手术治疗的大多数患者(71.4%)为B期,而接受手术联合辅助治疗的大多数患者(63.6%)为C期,仅接受手术治疗的7例患者中有5例局部复发.手术后辅助治疗的10例患者中有2例复发,局部和远处,分别。1例患者接受化疗,2例患者接受放化疗和新辅助化疗,然后进行放化疗。分别。复发率和持续率分别为35%和15%,分别。从首次治疗结束到复发的中位时间为20.9个月。2年和5年总生存率分别为83.9%和77.9%,无进展生存率分别为76.7%和61.0%,分别。
■60%的患者接受了多模式治疗,这似乎是对大多数患者有利的策略。